UK-based artificial intelligence (AI) firm InstaDeep is to be acquired by immunotherapy specialist BioNTech for $440 million plus up to $243 million in mileston 10 January 2023
Anglo-Irish company Amryt Pharma has long held ambitions of following in the footsteps of Shire, the rare diseases company that was acquired by Takeda four year 9 January 2023
French pharma firm Ipsen is to acquire the liver disease specialist Albireo, a company focused on the therapeutic potential of bile-acid modulators. 9 January 2023
Boston-based Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, has announ 9 January 2023
US immunology specialist Acelyrin has acquired ValenzaBio, a privately-held company developing therapies for autoimmune and inflammatory diseases, in an all-sto 5 January 2023
Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has announced the launch of Kaleibe, a herpes simplex virus (HSV) gene 14 December 2022
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news